RayzeBio, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.rayzebio.com
Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06726161
- Locations
- ๐บ๐ธ
Research Facility, Grand Rapids, Michigan, United States
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1
Recruiting
- Conditions
- Metastatic Breast CancerAdvanced Breast CancerHER2-negative Breast CancerER+ Breast Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06590857
- Locations
- ๐บ๐ธ
Research Facility, Seattle, Washington, United States
๐บ๐ธResearch Facilty, Salt Lake City, Utah, United States
Study of RYZ101 in Combination with SoC in Subjects with SSTR+ ES-SCLC
Phase 1
Recruiting
- Conditions
- SCLC,Extensive Stage
- Interventions
- Drug: RYZ101 Dose Level 1Drug: RYZ101 Dose Level 2Drug: RYZ101 Dose Level 3Drug: RYZ101 Dose Level -1
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05595460
- Locations
- ๐ต๐ท
Research Facility, San Juan, Puerto Rico
๐บ๐ธReserach Facility, Lexington, Kentucky, United States
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Phase 3
Recruiting
- Conditions
- GEP-NETPancreatic NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoid TumorCarcinoid
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT05477576
- Locations
- ๐ช๐ธ
Research Facility, Zaragoza, Spain
ยฉ Copyright 2025. All Rights Reserved by MedPath